Epsilon Healthcare Limited
EPN.ASXHealth Care
EPN is a diversified global healthcare and pharmaceuticals company. EPN owns a number of medicinal cannabis assets including the largest cannabis manufacturing facility in the Southern Hemisphere.
Market Data
$0.022
-0.0%$8.6M
-100000.0x
$-0.004
0.00%
-0.3%
Latest Earnings
Preliminary Final Report
27 February 2026
Epsilon Healthcare delivered a strong recovery in FY2025, with revenue surging 68% to $9.4M driven by CDMO manufacturing growth and the successful launch of a new Pharmacy division, though the company remains unprofitable with a loss of $2.1M (improving 63% from prior year's $5.5M loss). The turnaround reflects elimination of one-off voluntary administration costs and improved operational discipline, positioning the business for sustainable growth as manufacturing facility utilization increases. Key points: Revenue growth of 68% to $9.4M, driven by strong CDMO segment performance and early success of new Pharmacy division ($1.2M annualized revenue in first year); Net loss improved significantly by 63% to $2.1M from $5.5M prior year, reflecting elimination of one-off voluntary administration costs ($1.2M reduction in non-recurring expenses); Gross margin strong at 61.3% despite COGS increase proportional to revenue growth; underlying cost base reduced by $1.1M+ through operational efficiency
Recent Announcements
Becoming a substantial holder
Cyrene Holdings Pty Ltd became a substantial holder in Epsilon Healthcare Limited on 3 July 2026, acquiring 20,271,121 ordinary fully paid shares (5.21% voting power) for A$70,000 (A$0.02 per share).
Preliminary Final Report
Epsilon Healthcare delivered a strong recovery in FY2025, with revenue surging 68% to $9.4M driven by CDMO manufacturing growth and the successful launch of a new Pharmacy division, though the company remains unprofitable with a loss of $2.1M (improving 63% from prior year's $5.5M loss). The turnaround reflects elimination of one-off voluntary administration costs and improved operational discipline, positioning the business for sustainable growth as manufacturing facility utilization increases. Key points: Revenue growth of 68% to $9.4M, driven by strong CDMO segment performance and early success of new Pharmacy division ($1.2M annualized revenue in first year); Net loss improved significantly by 63% to $2.1M from $5.5M prior year, reflecting elimination of one-off voluntary administration costs ($1.2M reduction in non-recurring expenses); Gross margin strong at 61.3% despite COGS increase proportional to revenue growth; underlying cost base reduced by $1.1M+ through operational efficiency
Get real-time alerts for EPN
Receive AI-powered earnings summaries and instant notifications when Epsilon Healthcare Limited releases results.
Register Free